Unresectable Liver Cancer Trial Misses Key Endpoint
A phase 2 clinical trial for a triple immunotherapy regimen in patients with unresectable liver cancer failed to meet its primary efficacy endpoint. Consequently, the study will not advance to phase 3 testing.
Why it matters
The failure highlights the ongoing difficulty in finding effective first-line systemic treatments for advanced hepatocellular carcinoma.
A TRIPLE immunotherapy regimen showed no added benefit in patients with unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer, according to phase 2 results from the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial. The findings do not support adding low-dose ipilimumab to atezolizumab plus bevacizumab as a first-line treatment in this setting.
The article reports clinical trial results objectively without emotive language or political framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in